Physician profile
Benjamin O Dy
NPI 1831253368
$15,032.99
in general payments reported to CMS, 2019-2025
40 companies · $1,985 in 2025
The $1,985 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,899 · 2020: $1,871 · 2021: $3,069 · 2022: $2,397 · 2023: $1,967 · 2024: $1,846 · 2025: $1,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,791 · Education: $7.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,790.77 |
| Education | $7.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,650.58 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,722.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,487.01 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Amgen INC. | $1,258.79 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,251.20 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $972.16 | 2019-2024 | |
| Lilly USA, LLC | $915.08 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $780.87 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $580.44 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $504.39 | 2019-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $291.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $247.52 | 2021-2023 | Livalo, Seglentis |
| Nestle Healthcare Nutrition INC. | $241.81 | 2021-2023 | |
| Lundbeck LLC | $203.03 | 2021-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $164.28 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.